Kornimate/medical-research-clean huggingface dataset:
probiotics in infants with gastroschisis

Conditions: Gastroschisis

Summary: infants born with gastroschisis usually require surgery shortly after birth. after surgery the intestine is often unable to digest human milk or formula for weeks or months. during this time the baby has to remain in the hospital to receive special nutrition through an iv. how bacteria colonize the intestine in these babies is unknown. probiotics are bacteria that appear to have beneficial effects on digestion. this study will test whether giving probiotic bacteria to babies after surgery for gastroschisis will change the bacteria in the intestine to be more like those of a healthy breast-fed baby.

infants with gastroschisis have decreased intestinal motility. this decrease in intestinal motility delays the introduction and advancement of feeds which prolongs hospitalization. the use of probiotic bacteria may improve intestinal motility. it is unknown whether the intestinal microbiota of infants with gastroschisis differs from that of healthy infants without gastroschisis and whether probiotics will change the microbiota. the primary outcome in this study is the composition of the fecal microbiota in infants with gastroschisis following surgical correction treated with bifidobacterium infantis or placebo. we will also look at differences in hospital length of stay.

Eligibility criteria:
inclusion criteria: * gastroschisis * born at or transferred to uc davis children's hospital exclusion criteria: * none

Keywords: probiotic bifidobacteria intestinal motility
to investigate the clinical efficacy of an experimental toothpaste

Conditions: Gingivitis

Summary: the objective of this study is to evaluate the effect of an experimental toothpaste on maintaining gingival health over a 24 week period measured through modified gingival index, bleeding, plaque, and plaque bacteria. prior to commencing study treatment, subjects will undergo a dental prophylaxis followed by a 2 week period of oral hygiene instruction and weekly professional tooth cleaning to bring the subjects to their optimum gingival health prior to commencing study treatment.


Eligibility criteria:
inclusion criteria: * healthy subjects aged 18 years and older * a minimum of 20 permanent gradable teeth * for baseline eligibility, subjects must have a minimum modified gingival index score of 1.5-2.3.

Keywords: plaque toothpaste gingivitis
subclavian vein catheterization_seldinger vs modified seldinger

Conditions: Brain Neoplasm; Intracranial Aneurysm; Cerebrovascular Moyamoya Disease

Summary: seldinger technique is a minimally invasive technique in which the practitioner accesses the target vessel with a small bore needle, then dilates to the size required for the catheter. contrarily, modified seldinger technique(guiding sheath-over-the-needle technique) use needle that is covered with guiding sheath. both technique is widely used in central venous catheterization, however, few researches have been investigated to compare success rate or complications of both methods.

the major complications of central venous catheterization through subclavian vein, are unintended arterial puncture, pneumothorax, hemothorax, malposition of catheter etc,. we assume that using modified seldinger technique (mst), guiding sheath is easily slid over the needle, providing stable route into the vessel lumen relatively. we aimed to compare the seldinger technique and modified seldinger technique(mst) on success rate and complications during subclavian central venous catheterization in this prospective, randomized , controlled trials.

Eligibility criteria:
inclusion criteria: * patient scheduled for surgery under genearl anesthesia and subclavian vein central catheterization exclusion criteria: * patient who does not agree to the study * inflammation or infection on catheterization site * contralateral diaphragmatic dysfunction * anatomic anomalies of subclavian artery or vein/clavicle * previous lung surgical history * patient who has ventriculoperitoneal shunt or chemoport on same side * patient who has pneumo/hemothorax or lung parenchymal disease
automated 3d ultrasound-based surveillance of arteriovenous fistula maturation for post-operative hemodialysis patients

Conditions: Arteriovenous Fistula; Arteriovenous Graft

Summary: this is a two stage, prospective, multi-center study to evaluate the echomark and echosure devices in patients undergoing peripheral arteriovenous fistula creation for hemodialysis access.

this is stage 1 of a 2 stage protocol, targeting to enroll 60 patients in prospective, single arm, non-randomized, multi-center observational study to record objective data in patients undergoing upper extremity arteriovenous fistula construction with autologous tissue for the purpose of eventual hemodialysis access, in whom the echomark is placed at the site of vascular anastomosis. follow-up visits include echosure and duplex imaging.

Eligibility criteria:
inclusion criteria: * age \> 18 years * patients presenting for upper extremity arteriovenous fistula construction with autologous tissue for the purpose of eventual hemodialysis access where the surgeon has selected echomark and echosure as the optimal method of vascular monitoring based on clinical assessment and plan * patient is able to sign informed consent and able to participate in all testing associated with this clinical investigation * women of childbearing potential have a negative pregnancy test exclusion criteria: * age \<18 years old * patient unable to sign informed consent * patient participating in another investigational device or pharmacological study * prisoner or patient from vulnerable populations as defined in 45 cfr 46.
expression of toll-like receptors 3 , 7 and 9 in peripheral blood mononuclear cells of covid-19 patients

Conditions: COVID-19 Respiratory Infection

Summary: the aim of the study is to assess the expression of tlr 3, 7, and 9 in the population of peripheral blood mononuclear cells (pbmc) and in b lymphocytes (cd19+), t lymphocytes (cd4+ and cd8+) using flow cytometry in relation to the clinical parameters and outcome of covid 19 patients .

abnormal stimulation of innate immunity may have a great influence on the immunopathogenesis of covid 19 disease .the involvement of innate immunity receptors-toll-like receptors (tlr)-in the pathogenesis of covid 19 is not adequately studied. the activation of these receptors by specific ligands is thought to initiate autoimmune processes\[1\]. tlr stimulation leads to increased expression of proinflammatory cytokines (il-6, ifn

Eligibility criteria:
inclusion criteria: * patients ≥18 years old of both genders. * patients diagnosed as confirmed covid-19 when they have a positive result of rt-pcr for sars-cov-2 rna or confirmed diagnosis by typical clinical picture and radiological methods , according to the who and egyptian ministry of health and population (moh) definitions, at assiut university hospital. exclusion criteria: * children less than 18 years. * patients refusal to participate in the study
simplex high viscosity bone cement in primary total knee arthroplasty

Conditions: Osteoarthritis

Summary: in this study the investigators propose to monitor subjects who have received triathlon total knee components inserted with hv cement. the primary outcome will be fixation of the tibial implant component as assessed with rsa and to determine the functionality of patients after surgery using self-reported questionnaires. this is a historical control study, comparing the study cohort to a previous group with triathlon implants and the long-standing simplex t cement. the secondary outcomes are inducible displacements of the implants as well as a qualitative evaluation of the cement handling characteristics performed by the operating room staff.


Eligibility criteria:
inclusion criteria: * symptomatic arthritis of the knee indicating primary total knee arthroplasty * between the ages of 21 and 80 inclusive * patients willing and able to comply with follow-up requirements and self-evaluations * ability to give informed consent exclusion criteria: * active or prior infection * medical condition precluding major surgery * severe osteoporosis or osteopenia * neuromuscular impairment * significant co-morbidity affecting ability to ambulate

Keywords: total knee arthroplasty
influence of the neuromuscular blockade on mask ventilation

Conditions: Complication of Ventilation Therapy; Observation of Neuromuscular Block

Summary: mask ventilation during induction of anesthesia can be improved by administration of neuromuscular blocking agents (nmbas). nmbas are usually administered after testing mask ventilation; however, muscle relaxants may improve mask ventilation and they do not alter mask ventilation. thus, growing evidence suggests to administer muscle relaxants before testing mask ventilation. we will study different dosages of rocuronium; we assume that higher dosages of rocuronium will improve mask ventilation compared with lower dosages.

mask ventilation during induction of anesthesia can be improved by administration of neuromuscular blocking agents (nmbas). nmbas are usually administered after testing mask ventilation; however, muscle relaxants may improve mask ventilation and they do not alter mask ventilation. thus, growing evidence suggests to administer muscle relaxants before testing mask ventilation.we will administer rocuronium 0.3 mg/kg, 0.6 mg/kg, 0.9 mg/kg and saline (placebo group) before starting with mask ventilation. we will grade mask ventilation based on various scores before and after rocuronium application. afterwards patient's tracheas will be intubated. we assess risk factors for difficult mask ventilation. we hypothesize that rocuronium 0.9 mg/kg will be superior to rocuronium 0.3 mg/kg and saline.

Eligibility criteria:
inclusion criteria: * patients with asa i-iii * required tracheal intubation * informed consent exclusion criteria: * known allergy against anesthetics * known difficult airway

Keywords: muscle relaxants
a translational systems medicine approach to provide predictive capacity for therapy response in advanced or metastatic malignant melanoma

Conditions: Advanced Melanoma; Metastatic Melanoma

Summary: this is an exploratory prospective translational multicentre study. melanoma is the 5th most common cancer diagnosed in ireland and its incidence among women and men is above the european average. following treatment the elimination of cancer cells ultimately occurs by the activation of apoptotic cell death pathways. the sys-act approach builds on a combination of mathematical systems of modelling, quantitative biochemistry and cell biology, and specifically predicts the drug responsiveness of melanoma cell lines to various apoptosis-inducing treatments. the investigators propose to validate the sys-act approach and application in a translational systems medicine study.


Eligibility criteria:
inclusion criteria: 1. patients ≥ 18 years of age. 2. patient must be able to give own signed informed consent. 3. patients that present with advanced or metastatic (stage iii/iv) malignant melanoma of the skin. 4. patients that are planned to receive either: * adjuvant treatment * 1st line treatment for metastatic disease * 2nd line treatment for metastatic disease 5. patients with prior adjuvant treatment are allowed. 6. patients receiving planned standard treatment of one or more of the following: * chemotherapy regimens containing dtic, tmz and/or cisplatin * immunotherapy (for example ipilimumab and/or anti-pd-l1/pd-1 therapies) * braf and/or mek inhibitors 7. patients were ffpe and fresh frozen tissue is available (both mandatory). exclusion criteria: -

Keywords: advanced melanoma metastatic melanoma fresh frozen tissue ffpe tissue
efficacy and safety of 'immuncell-lc group' and 'non-treatment group' in nexavar treated patients for advanced hcc

Conditions: Advanced Hepatocellular Carcinoma

Summary: "immuncell-lc" in aspects of therapeutic efficacy and safety when administered with nexavar to advanced hepatocellular carcinoma patients when compared with the control group who did not receive administration of the drug.

* primary outcome compare clinical efficacy of group treated with cell therapeutic immuncell-lc evaluated by progression free survival with that of untreated group * secondary outcome compare clinical efficacy of group treated with immuncell-lc, a drug for treating advanced hepatocellular carcinoma evaluated by overall survival, disease control rate, changes of alpha feto protein(afp) figures from baseline to the last observation date and that of untreated group and evaluate adverse reactions, clinical pathological tests and its safety.

Eligibility criteria:
inclusion criteria: * patients who have consented to the study by providing signature of self, guardian or legal representative * the patient is more than 20 and less than 80 years old * the patient is diagnosed as hepatocellular carcinoma by pathological/radiological test and in the stage of iii or iv * child-pugh score should be a * ecog performance status (ecog-ps) is less than 2 or equal to * patients who receiving or ready for nexavar treatment * patients who satisfy the following conditions of the blood test and kidney function test * absolute granulocyte count is bigger than 1,000/µl * hemoglobin is bigger than 8.5 g/dl * platelet count is bigger than 5x10\^10/l * blood urea nitrogen(bun) or creatinine 1.5xupper normal limit exclusion criteria: * patients who are immune deficient or have a history of auto-immune diseases (ex. rheumatoid arthritism, systemic lupus erythematosus, vasculitis, multiple sclerosis, adolescent insulin-dependent diabetes mellitus, etc.) * patients who have a history of malignant tumors in the recent 5 years prior to the study with the exception of basal cell carcinoma, local prostate cancer, and cervical cancer, liver cancer. * patients who had anti-cancer medication before the study with the exception of nexavar * patients who has serious dysfunction in other organs by sub-investigator's opinion * patients has serious allergic-history by sub-investigator's opinion * patients has serious mental disease sub-investigator's opinion * pregnant women, nursing mother of having intention of being pregnant during the study * patients who participated in other clinical trial within 4 weeks before this study

Keywords: immuncell-lc, advanced hepatocellular carcinoma
accelerated biological aging is associated with increased risk of t2dm in the masld population

Conditions: Type 2 Diabetes Mellitus (T2DM); Metabolic Dysfunction-Associated Steatotic Liver Disease; Biological Age

Summary: the association between biological aging and type 2 diabetes mellitus (t2dm) incidence in individuals with and without metabolic dysfunction-associated steatotic liver disease (masld) remains unclear.we assessed biological age by calculating phenotypic age (phenoage), klemera-doubal method (kdmage), and homeostatic dysregulation (hdage). to examine the association of biological ageing with the risk of t2dm, cox regression models were conducted. furthermore, we applied survival analysis, restricted cubic spline models and population attributable fraction (paf) to further evaluate the association between biological ageing and t2dm incidence.


Eligibility criteria:
inclusion criteria: 1. abdominal ultrasound data available in annual health check-up records 2. at least one of the following five metabolic indicators recorded annually: (1) body mass index (bmi) or waist circumference (2) blood pressure (3) serum triglycerides (4) high-density lipoprotein cholesterol (hdl-c) (5) fasting plasma glucose or glycated hemoglobin (hba1c) exclusion criteria: 1. age \ 90 years 2. other causes of hepatic steatosis (e.g., alcoholic liver disease or hepatitis b infection) 3. type 2 diabetes mellitus at baseline 4. missing baseline data for any of the following variables: systolic blood pressure, albumin, alkaline phosphatase, blood urea nitrogen, creatinine, glycated hemoglobin (hba1c), total cholesterol, lymphocyte percentage, white blood cell count, mean corpuscular volume, uric acid, fasting plasma glucose, and red cell distribution width (rdw)
cryo balloon for residual barrett's esophagus

Conditions: Barrett's Esophagus

Summary: this study is being done to see if treating residual barrett's esophagus after previously having undergone radiofrequency ablation or endoscopic mucosal resection can be eliminated with focal cryotherapy.


Eligibility criteria:
inclusion criteria: * age \> 18 years old * able to provide informed consent * patients with unifocal or multifocal be with 2 cm who have failed at least 2 serial rfa or other endoscopic therapy such as endoscopic mucosal resection, exclusion criteria: * age younger than 18 years old * presence of esophageal varices * esophageal stricture precluding passage of an endoscope * inability to provide informed consent * esophageal cancer (t2 and above) * coagulopathy with inr \> 2.0, thrombocytopenia with platelet counts \< 50,000 * pregnancy (if required a pregnancy test would be performed as part of routine clinical care)

Keywords: barrett's high grade dysplasia ablation cyrotherapy
evaluation of different phone solutions in ci and hearing aid users and bimodal recipients

Conditions: Hearing Loss, Binaural; Hearing Loss, Monaural

Summary: communication on telephone is challenging for people with hearing loss. for hearing aid users, for instance, the inventions for improving speech intelligibility on the phone range from an integrated tele coil and individual hearing programs to specially designed phone devices. no formal studies involving these devices have been carried out with ci users. thus, this comparative study includes hearing aid as well as ci and bimodal users to evaluate different hearing solutions for communication on telephone in terms of intelligibility and ease of use.

communication on telephone is challenging for people with hearing loss, due to a number of factors: * the lack of visual cues (lip-reading), * the lack of binaural abilities, * the presence of (loud) background noise in a variety of listening situations, * a modified speech signal due to reduced frequency bandwidth and * difficulties coupling the phone to the ci. for hearing aid users, for instance, the inventions for improving speech intelligibility on the phone range from an integrated tele coil and individual hearing programs to specially designed phone devices. no formal studies involving these devices have been carried out with ci users. thus, this comparative study includes hearing aid as well as ci and bimodal users to evaluate the different hearing solutions for communication on telephone in terms of intelligibility and ease of use: * phonak dect - cordless telephone for ha-, ci- users and bimodal users * phonak easycall - accessories for bluetooth capable mobile telephones for ha-, ci- and bimodal users * phonak duophone - streaming function, which provides the speech signal to both ears

Eligibility criteria:
inclusion criteria: * unilateral ha users with srt of better (lower) than + 3 db * bilateral ha users with srt of better (lower) than 0 db * unilateral ci users: unilaterally implanted with an advanced bionics cii, hires90k or advantage implant 1-year acclimatization time after implantation at least 20% correct for a sentence test delivered with a snr of + 10 db, or a srt of better (lower) than + 15 db * bimodal (ci + ha) users: unilaterally implanted with an advanced bionics cii, hires90k or advantage implant ci side: at least 20% correct for a sentence test delivered with a snr of + 10 db, or a srt of better (lower) than + 15 db ha side: unaided threshold ≤ 80 db at least for frequencies up to 500 hz * all users: informed consent as documented by signature ability for speech understanding in the presence of competing noise without any assistance from lip-reading ability to give subjective feedback in a certain listening situation first language: german or swiss-german exclusion criteria: * all users: difficulties additional to hearing impairment that would interfere with the study procedures acute inflammation or pain in head-/neck area dizziness age of participants \ 80 years

Keywords: hearing aid usage (monaural, binaural) cochlear implant usage (monaural, binaural) hearing aid and cochlear implant usage (monaural)
post-operative imaging in high grade glioma: is management influenced?

Conditions: Glioma

Summary: magnetic resonance imaging (mri) is likely to play an important role in the management of high grade glioma. appropriate and timely neuroimaging in the follow up period is believed to be crucial in making subsequent management decisions. however, there is a paucity in the literature providing evidence to support this. the aim of this study is to determine whether neuroimaging performed at each component of the patient pathway after initial high grade glioma treatment, actually results in a real change in management (as opposed to a perceived change in management). the main emphasis is on all imaging used at the time of a mdm, however, we will also study specifically dynamic susceptibility contrast-enhanced (dsc) mri and dynamic contrast enhanced (dce) mri. the study is in the format of mock mdms to be compatible with real life decision making. using retrospective identical information available at the mdm i.e. compiled recent correspondence, histopathological and molecular information, the mdm members (oncology nurse, oncologist, neurosurgeon, neuroradiologist, pathologist/molecular scientist) will prospectively determine the patient management with and without the imaging.


Eligibility criteria:
inclusion criteria: * histologically proven hgg patients (grade iii and iv who criteria) * underwent surgery, radiotherapy and chemotherapy regimen according to 2018 nice guidelines (1) * \>=18 years old * has follow-up mri imaging (t1, t2, flair and t1 with contrast enhancement) and also dsc and dce imaging * evaluated at mdt meetings between march 2018 and march 2020. exclusion criteria: * patients who have insufficient clinical and radiological follow-up
improving scientific rigor of renal clinical endpoints for sickle cell anemia

Conditions: Sickle Cell Disease; Renal Disease; Glomerular Disease

Summary: the investigators will attempt to develop a more accurate equation to estimate egfr in pediatric and adult sickle cell patients

200 pediatric and 200 adult sca participants will undergo mgfr using iohexol at baseline and at one year. on the same day, participants will undergo clinical and laboratory variables important for developing an egfr equation. from baseline data, the investigators will perform a training and validation cohort of biologically relevant predictor variables to develop a novel equation. then the investigators will compare the novel sca egfr equation to the established egfr equation. from one year data, the investigators will determine the longitudinal concordance between pediatric and adult novel and standard egfr equations with mgfr and variables that may alter longitudinal inferences. in a subset of 30 adult participants, the investigators will also evaluate the correlation between mgfr using iohexol and a novel measure of mgfr that is more time efficient

Eligibility criteria:
inclusion criteria: * sca patients (hbss and sb0 thalassemia) * age: 5.0-50.0 at enrollment exclusion criteria: * recent sca complication associated with hospitalization (within 30 days) or ed visit (within 14 days) * current aki defined as \>0.3mg/g increase in scr from prior visit * known history of anaphylaxis with contrast agent or known pregnancy